CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Oragenics opens second site for ONP-002 Phase IIa trial

Phase 2ONP-002Neutral
AI Analysis

Summary

Oragenics activated a second clinical trial site at Alfred Hospital for its Phase IIa trial of ONP-002, a lead candidate for treating concussion and mild traumatic brain injury.

Clinical Trial Data

Phase

Phase IIa

Importance:3/10
Sentiment:
0.20
Phase IIaclinical trialsite activationONP-002concussionmTBI
Related Companies

Read the original article

Published by Clinical Trials Arena on May 6, 2026 10:17 AM

Read Original